Connect your AI

PTHS PTHS Number of approved products

Other financials

Income statement

Revenue$10.9M—

Gross profit$9.2M—

Operating income-$13.1M-614%

Net income-$10.2M-420%

EPS (diluted)-$3.09+3.7%

Balance sheet

Cash & equivalents$32.0M+24,250%

Total debt$29.6M—

Total equity$35.1M+937%

Total assets$145.4M+15,855%

Cash flow

Operating cash flow-$13.1M-1,977%

CapEx$194.0K—

Free cash flow-$13.3M-2,008%

Valuation

Market cap$98.22M+75.4%

Enterprise value$95.89M—

P/S3.6×—

Profitability

Gross margin79.6%—

Operating margin-157.7%—

Net margin-186.2%—

FCF margin-60.8%—

Returns & leverage

Return on equity-333.8%—

Debt / equity0.8×—

Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept pths:NumberOfFDAApprovedProducts.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's number of approved products.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is PTHS's number of approved products?: PTHS (PTHS) reported number of approved products of 3 in Q1 2026.